You are here: Home / Protocols / Breast Reference Set Application: Karen Abbott- University of Arkansas (2013)

Breast Reference Set Application: Karen Abbott- University of Arkansas (2013)

378
Feng, ZidingFred Hutchinson Cancer Research Center
LPHA,and Periostin
Glycomics
Breast and Gynecologic Cancers Research

We are evaluating whether detection of a tumor-specific N-linked glycosylation known as B 1,6 branched N-glycan present on the glycoprotein periostin in breast cancer will be useful as a new biomarker for the detection of breast cancer in patient plasma and serum. We have completed an initial study using samples with known inavasive ductal breast carcinoma diagnosis and the results look very promising. Therefore, we would like to proceed with our analysis of this potential biomarker for breast cancer diagnosis by analyzing the blinded samples in breast reference set 1.

Validating B 1,6 as a biomarker for the early detection of breast cancer. Then continuing to validate L-PHA with the use of Breast Reference Set 2 samples.
The analysis for LPHA-periostin will be similar. In each case, data will be fit to the fixed-effects linear model yij = u + ai + Bj+ eij, wehre yij is the level, u is the grand mean, ai represent the pairing effect (age-matching), bj the tumor/normal effect,and eij random variation. Transformations of the response levels will be analyzed with the method of Box and Cox (1964); based on the preliminary data we anticipate the log transformation will be adequate. Basic plots of the transformed data will be analyzed for skewness and outliers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/27/2019
Thank you to everyone who made the 11th EDRN Scientific Workshop a success. The next EDRN Steering Committee Meeting is from Tuesday-Thursday, March 31-April 2, 2020 in Tempe, AZ.
Announcement



 
This icon signifies that something is happening and we kindly ask you to please wait